CLDF Title
Home | Contact Us | Bookmark
HBV HE HCC HCV
About CLDF Centers of Educational Expertise  
CME Dinner Meetings Telewebs Webcasts Slide Library Abstract Library Conference Highlights
 
Back  
 
Reuters Health Information (2005-10-05): EU OKs briefer Schering-Plough hepatitis C therapy

Regulatory

EU OKs briefer Schering-Plough hepatitis C therapy

Last Updated: 2005-10-05 14:33:39 -0400 (Reuters Health)

NEW YORK (Reuters) - Schering-Plough Corp. on Wednesday said European regulators approved a 24-week course of treatment with its combination therapy for some patients infected with the most common form of hepatitis C, rather than the standard 48-week regimen.

The company said the European Commission approved the shorter treatment for a "subgroup" of patients with low bloodstream levels of the genotype 1 form of the virus, whose virus levels then fall to undetectable levels during the first four weeks of treatment.

"This is the only treatment regimen approved in the European Union for a 24-week course of therapy in certain genotype 1 patients," the Kenilworth, New Jersey-based company said in a release.

 
 
 
 
                 
 
HBV
Webcasts
Slide Library
Abstract Library
 
HE
CME Dinner Meeting
Webcasts
Slide Library
Abstract Library
 
HCC
Slide Library
Abstract Library
 
 
HCV
Webcasts
Slide Library
Abstract Library
 
CLDF Follow Us
   
 
About CLDF
Mission Statement
Board of Trustees
Board of Advisors
CLDF Supporters
 
Other Resources
Liver News Library
Journal Abstracts
Hep C Link to Care
 
Centers of
Educational Expertise
Regional Map
     
   
  The Chronic Liver Disease Foundation is a non-profit organization with content developed specifically for healthcare professionals.
© Copyright 2012-2014 Chronic Liver Disease Foundation. All rights reserved. This site is maintained as an educational resource for US healthcare providers only.
Use of this Web site is governed by the Chronic Liver Disease Foundation terms of use and privacy statement.